GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (CHIX:BIONz) » Definitions » LT-Debt-to-Total-Asset

BB Biotech AG (CHIX:BIONZ) LT-Debt-to-Total-Asset : 0.11 (As of Sep. 2024)


View and export this data going back to 2012. Start your Free Trial

What is BB Biotech AG LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. BB Biotech AG's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.11.

BB Biotech AG's long-term debt to total assets ratio declined from Sep. 2023 (0.12) to Sep. 2024 (0.11). It may suggest that BB Biotech AG is progressively becoming less dependent on debt to grow their business.


BB Biotech AG LT-Debt-to-Total-Asset Historical Data

The historical data trend for BB Biotech AG's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BB Biotech AG LT-Debt-to-Total-Asset Chart

BB Biotech AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.02 0.10 0.12 0.12

BB Biotech AG Quarterly Data
Mar17 Jun17 Dec17 Dec18 Dec19 Dec20 Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.12 0.12 0.12 0.11

BB Biotech AG LT-Debt-to-Total-Asset Calculation

BB Biotech AG's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=304.9/2637.154
=0.12

BB Biotech AG's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )/Total Assets (Q: Sep. 2024 )
=274.3/2506.187
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BB Biotech AG  (CHIX:BIONz) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


BB Biotech AG LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of BB Biotech AG's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


BB Biotech AG Business Description

Address
Schwertstrasse 6, Schaffhausen, CHE, CH-8200
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market, and is one of the investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system.

BB Biotech AG Headlines

No Headlines